

**Anti-IL-17Ra / CD217 Reference Antibody (brodalumab)
Recombinant Antibody
Catalog # APR10467****Specification**

Anti-IL-17Ra / CD217 Reference Antibody (brodalumab) - Product Information

Application	FC, E, FTA
Primary Accession	O96F46
Reactivity	Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG2SA
Calculated MW	144.06 KDa

Anti-IL-17Ra / CD217 Reference Antibody (brodalumab) - Additional Information**Target/Specificity**

IL-17Ra / CD217

Endotoxin

< 0.001EU/ µg, determined by LAL method.

Conjugation

Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

Anti-IL-17Ra / CD217 Reference Antibody (brodalumab) - Protein Information**Name** IL17RA ([HGNC:5985](#))**Synonyms** IL17R**Function**

Receptor for IL17A and IL17F, major effector cytokines of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Receptor for IL17A (PubMed: [17911633](http://www.uniprot.org/citations/17911633)), PubMed: [9367539](http://www.uniprot.org/citations/9367539)). Receptor for IL17F (PubMed: [17911633](http://www.uniprot.org/citations/17911633)), PubMed: [19838198](http://www.uniprot.org/citations/19838198)). Binds to IL17A with higher affinity than to IL17F (PubMed: [17911633](http://www.uniprot.org/citations/17911633)). Binds IL17A and IL17F homodimers as part of a heterodimeric complex with IL17RC (PubMed: [16785495](http://www.uniprot.org/citations/16785495)). Also binds

heterodimers formed by IL17A and IL17F as part of a heterodimeric complex with IL17RC (PubMed:18684971). Cytokine binding triggers homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter, leading to TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways, ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation (PubMed:16785495, PubMed:17911633, PubMed:18684971, PubMed:21350122, PubMed:24120361). Involved in antimicrobial host defense primarily promoting neutrophil activation and recruitment at infection sites to destroy extracellular bacteria and fungi (By similarity). In secondary lymphoid organs, contributes to germinal center formation by regulating the chemotactic response of B cells to CXCL12 and CXCL13, enhancing retention of B cells within the germinal centers, B cell somatic hypermutation rate and selection toward plasma cells (By similarity). Plays a role in the maintenance of the integrity of epithelial barriers during homeostasis and pathogen infection. Stimulates the production of antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal epithelial cells, limiting the entry of microbes through the epithelial barriers (By similarity). Involved in antiviral host defense through various mechanisms. Enhances immunity against West Nile virus by promoting T cell cytotoxicity. Contributes to Influenza virus clearance by driving the differentiation of B-1a B cells, providing for production of virus-specific IgM antibodies at first line of host defense (By similarity). Receptor for IL17C as part of a heterodimeric complex with IL17RE (PubMed:21993848).

Cellular Location

[Isoform 1]: Cell membrane; Single-pass type I membrane protein

Tissue Location

Widely expressed..


Anti-IL-17Ra / CD217 Reference Antibody (brodalumab) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-IL-17Ra / CD217 Reference Antibody (brodalumab) - Images





Anti-IL-17Ra / CD217 Reference Antibody (brodalumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-IL-17Ra / CD217 Reference Antibody (brodalumab) is more than 99.05%, determined by SEC-HPLC.